5PSQ-138 Satisfaction with cabotegarvir and rilpivirine long-acting in a real-world setting: preliminary data

<h3>Background and Importance</h3> Long-acting injectable antiretroviral therapy (LA-ART) represents a novel administration route as an alternative to daily oral antiretroviral treatment. <h3>Aim and Objectives</h3> To describe the satisfaction with medication, according to the HIVTSQ questionnaire, of patients in treatment with LA CAB+RPV in real-world setting. <h3>Material and Methods</h3> The RELATIVITY cohort is an ambispective study that includes patients treated in 37 Spanish hospitals. Eligible patients are over 18 years of age and have received their first dose before January 1, 2024. Between 9–14 month of treatment, a questionnaire was administered in an online format with QR code. The data were collected on the RedCap platform for subsequent analysis. The survey to be conducted is the ‘Satisfaction with Medication: HIVTSQ.¹ This survey comprises 12 core questions. The initial 11 questions assess satisfaction with the medication, with a maximum favourable score of 66 points. The final question pertains to pain or discomfort associated with the injection, with a maximum favourable score of 6 points. Higher scores are associated with greater satisfaction with the medication. <h3>Results</h3> The study included 205 patients from 13 hospitals in Spain. Median age of patients is 46.0 (38.2, 55.4) years and 88.7% males. In the global satisfaction score with medication (questions from 1 to 11), our group of patients has a median score of: 61.5 (54.0, 64.5). In the injection pain or discomfort score (question 12), our group of patients has a median score of: 4.5 (3.0, 6.0). <h3>Conclusion and Relevance</h3> Long-acting (LA) injectable antiretroviral therapy (ART) has been shown to be a well-tolerated alternative to daily oral antiretroviral treatment. The treatment aspects that received the lowest patient satisfaction ratings are flexibility and pain or discomfort. These findings support the implementation of LA-ART in clinical practice. <h3>References and/or Acknowledgements</h3> Murray M, Pulido F, Mills A, Ramgopal M, LeBlanc R, Jaeger H, Margolis D. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomised LATTE-2 study. <i>HIV Research &amp; Clinical Practice</i> (2019);<b>20</b>(4–5), 111–122. https://doi.org/10.1080/25787489.2019.1661696 <h3>Conflict of Interest</h3> No conflict of interest